Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Cybin Inc. has initiated the first-in-human dosing of CYB004 in a Phase 1 clinical trial, evaluating intravenous N,N-dimethyltryptamine (IV DMT) and CYB004 in healthy volunteers. Robust psychedelic effects were observed within two minutes, with no safety concerns reported.
May 24, 2023 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cybin Inc. has initiated the first-in-human dosing of CYB004 in a Phase 1 clinical trial, with no safety concerns reported.
The initiation of the first-in-human dosing of CYB004 in a Phase 1 clinical trial is a positive development for Cybin Inc. The absence of safety concerns in the initial participants indicates that the trial is progressing well, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100